Press release
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
Investor conference call and webcast scheduled for November 13, 2021, at 6:30 p.m. ET WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today
About this update from Incyte Corporation
[{"type":"text","content":"\nInvestor conference call and webcast scheduled for November 13, 2021, at 6:30 p.m. ET\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, held from November 10-14, 2021 in Washington, D.C and virtually.\n\n“We look forward to presenting data from multiple programs within Incyte’s immuno-oncology portfolio at this year’s SITC conference,” said Lance Leopold, M.D., Group Vice President, Immuno-Oncology, Incyte. “Data being presented from the retifanlimab POD1UM clinical program, including a late-breaking poster presentation highlighting results from the POD1UM-101 study; as well as results from a Phase 1 study evaluating an oral PD-L1 inhibitor in immune-checkpoint naïve patients with advanced solid tumors, demonstrate our commitment to addressing the needs of patients with historically difficult-to-treat cancers.”\n\nKey abstracts include:\n\nLate-Breaking Poster Presentation\n\nRetifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: Results from the POD1UM-101 Study (Abstract #956. Saturday, November 13, 7:00 a.m. – 8:30 p.m. ET)\n\nOral Presentation\n\nPhase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors (Abstract #529. Session: Concurrent Rapid Oral Abstract Presentation: Clinical. Saturday, November 13, 12:45 – 1:45 p.m. ET)\n\nPoster Presentation\n\nA Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma (MCC) (POD1UM-201) (Abstract #545. Friday, November 12, 7:00 a.m. – 8:30 p.m. ET)\n\nFull abstracts will be available on the SITC website and in the Journal for ImmunoTherapy of Cancer (JITC) on November 9, 2021. More information regarding the conference is available on the SITC website: https://www.sitcancer.org/2021/home.\n\nConference Call and Webcast\n\nIncyte will host an analyst and investor conference call and webcast on Saturday, November 13, 2021 from 6:30 – 7:30 p.m. ET to discuss its oral PD-L1 clinical development program, including data from INCB86550 which has been accepted for oral presentation at the SITC Annual Congress.\n\nThe live and archived webcast will be available via investor.incyte....